Related Experiment Video
Updated: May 30, 2026
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
[Pharmacological characterization of head and neck cancer in ex-vivo tests]
1HNO-Forschungslabor,Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde/Plastische Chirurgie, Universitätsklinikum Leipzig, Liebigstr. 21, 04103, Leipzig, Deutschland. Gunnar.Wichmann@medizin.uni-leipzig.de
Abstract:
Precise knowledge about the chance of success of a given pharmacologic therapy of head and neck squamous cell carcinoma (HNSCC) before starting therapy would be very desirable to guide the selection of the most suitable or the most efficient combination out of the ever-growing spectrum of available pharmaceuticals. This selection has hitherto been made at best on the basis of the availability of guideline-conformant and approved combinations according to results of published clinical studies and approved general effectiveness in HNSCC. However, the inhomogeneous biology of HNSCC depending on localization, varying metastatic behavior, TNM and UICC stage in the context of the patient's general condition and risk status according to lifestyle and occupational exposure make it impossible to accurately predict the success of pharmacological therapy regimens for the individual HNSCC based on today's clinical and pathohistological diagnostics. A solution may lie in the testing of biopsy specimens ex vivo before starting therapy. The present review describes recent advances in ex-vivo tests and discusses the requirements for their inclusion in the decision-making process.
Insights
Predicting head and neck squamous cell carcinoma (HNSCC) treatment success is challenging. Ex vivo testing of biopsy specimens offers a promising approach to personalize HNSCC pharmacologic therapy selection.
Area of Science:
- Oncology
- Pharmacology
- Translational Medicine
Context:
- Head and neck squamous cell carcinoma (HNSCC) presents heterogeneous biology, complicating treatment selection.
- Current treatment decisions rely on general guidelines and population-level effectiveness, not individual patient profiles.
- Accurate prediction of pharmacologic therapy success for individual HNSCC patients is currently limited.
Purpose:
- To review recent advances in ex vivo testing for HNSCC.
- To discuss the requirements for integrating ex vivo tests into clinical decision-making for HNSCC treatment.
Summary:
- Pharmacologic therapy for HNSCC requires precise prediction of treatment success for optimal drug selection.
- Ex vivo testing of biopsy specimens before therapy initiation is proposed as a solution to personalize HNSCC treatment.
- This review explores recent developments in ex vivo testing methodologies and their potential clinical application.
Impact:
- Enables personalized pharmacologic therapy selection for head and neck squamous cell carcinoma.
- Improves the efficiency of HNSCC treatment by guiding the choice of pharmaceuticals.
- Facilitates the integration of novel diagnostic tools into routine HNSCC clinical practice.
